OOIR: Observatory of International Research

Papers

(The H4-Index of Hypertension is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
2020 International Society of Hypertension Global Hypertension Practice Guidelines	1833
Renin-Angiotensin System Blockers and the COVID-19 Pandemic	363
Age and Multimorbidity Predict Death Among COVID-19 Patients	301
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension	236
Evidence and Recommendations on the Use of Telemedicine for the Management of Arterial Hypertension	174
Blood Pressure and Risks of Cognitive Impairment and Dementia	168
Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association	160
May Measurement Month 2019	155
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor	138
Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary	132
Trimethylamine-N-Oxide Promotes Age-Related Vascular Oxidative Stress and Endothelial Dysfunction in Mice and Healthy Humans	129
Elevated Blood Pressure in Childhood or Adolescence and Cardiovascular Outcomes in Adulthood	127
Management of Hypertension in the Digital Era	125
Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension	125
Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia	123
Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018	118
Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness	112
Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension	108
Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19	108
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension	104
Early and Supernormal Vascular Aging	100
ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic	96
Antihypertensive Drugs and COVID-19 Risk	93
Endothelium-Macrophage Crosstalk Mediates Blood-Brain Barrier Dysfunction in Hypertension	93
Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association	91

Discrimination and Hypertension Risk Among African Americans in the Jackson Heart Study	91
Genetic, Cellular, and Molecular Heterogeneity in Adrenals With Aldosterone-Producing Adenoma	89
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors	88
Evaluation of the Accuracy of Cuffless Blood Pressure Measurement Devices: Challenges and Proposals	88
Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease	86
Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine	80
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association	76
Association of Cardiovascular Risk Factors and Lifestyle Behaviors With Hypertension	75
Urate, Blood Pressure, and Cardiovascular Disease	74
Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005–2016	68
Microbial Peer Pressure	67
SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients	66
Machine Learning Strategy for Gut Microbiome-Based Diagnostic Screening of Cardiovascular Disease	66
Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure	65
Nonvalidated Home Blood Pressure Devices Dominate the Online Marketplace in Australia	65
COVID-19	64
SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk	64
Blood Pressure Control Among US Adults, 2009 to 2012 Through 2017 to 2020	64
Epithelial Sodium Channel and Salt-Sensitive Hypertension	63
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study	62
Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular Risk	62
Influence of Sex and Age on Muscle Sympathetic Nerve Activity of Healthy Normotensive Adults	60
Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit	60
Blood Pressure and Risk of Cardiovascular Disease in UK Biobank	59
Animal Models of Preeclampsia	58
Modest Sodium Reduction Increases Circulating Short-Chain Fatty Acids in Untreated Hypertensives	58
Blood Pressure Variability and the Risk of Dementia	58
Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2 , the Receptor for SARS-CoV-2 Infectivity	58
ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases	57
Physical Activity as a Critical Component of First-Line Treatment for Elevated Blood Pressure or Cholesterol: Who, What, and How?: A Scientific Statement From the American Heart Association	57
Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination	57
Visit-to-Visit Blood Pressure Variability Is Associated With Cognitive Decline and Incident Dementia	57
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study	57